Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors

Oncology

Volumn 69, Issue 3, 2005, Pages 202-207

  Kouroussis, Ch ^a   Androulakis, N ^b   Vamvakas, L ^b   Kalykaki, A ^b   Spiridonakou, S ^a   Kentepozidis, N ^a   Saridaki, Z ^a   Xiropoulou, El ^b   Georgoulias, V ^a,b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chemotherapy, weekly; Docetaxel; Doxorubicin; Pegylated liposomal doxorubicin

Indexed keywords

DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; METHYLPREDNISOLONE; ONDANSETRON; PROSTATE SPECIFIC ANTIGEN; RANITIDINE;

ADULT; AGED; ANEMIA; ANTIGEN DETECTION; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HUMAN; LACRIMATION; LUNG EDEMA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 26444440376     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087908     Document Type: Article

References (19)

1. Verweij J, Catimel G, Sulkes A, Sternberg C, et al: Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1995;31(suppl 4):21-24.
2. Tabernero J, Climent AM, Liuch A, Albanell J, et al: A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-1365.
3. Hainsworth DJ, Greco AF: The role of weekly docetaxel in the treatment of advanced non-small cell lung cancer. Clin Lung Cancer 2002;3(suppl 2):S17-S22.
4. Serke M, Schoenfeld N, Loddenkemper R: Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Anticancer Res 2004;24:1211-1216.
5. Seidman AD, Murphy B, Hudis C, McCaffrey J, et al: Activity of Taxol by weekly 1-hour infusion in patients with metastatic breast cancer: a phase II study and pharmacologic study (abstract). Proc Am Soc Clin Oncol 1997;16:148a.
6. Smith RE, Anderson SJ, Lembersky BC, Brown A, Mamounas E: Phase I trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel; project trial BP-57. Clin Breast Cancer 2004;5:208-215.
7. Syvanen K, Ekholm E, Anttila K, Salminen E: Immediate effects of docetaxel alone or in combination with epirubicin on cardiac function in advanced breast cancer. Anticancer Res 2003;23:1869-1873.
8. O'Brien R, Wigler N, Inbar M, Rosso R, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
9. Theodoulou M, Hudis C: Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004;15;100:2052-2063.
10. Uziely B, Jeffers S, Isacson R, Kutsch K, et al: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1998;16:683-691.
11. Judson J, Radford JA, Harris M, Blay JV, et al: Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877.
12. Chan S, Davidson N, Juozaityte E, Erdkamp F, et al: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004;15:1527-1534.
13. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, World Health Organization, 1979.
14. National Cancer Institute: Guidelines for Reporting Adverse Drug Reactions. Bethesda, National Cancer Institute, 1978.
15. Budman DR, Calabro A, Kreis W: Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13:1011-1016.
16. Schwonzen M, Kurbacher C, Mallman P: Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000;11:681-685.
17. Sparano JA, Malik U, Rajdev L, Sarta C, et al: Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001;19:3117-3125.
18. Briasoulis E, Karavasilis V, Tzamakou E, Rammou D, et al: Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 2004;53:452-457.
19. Treat J, Greenspan, Forst D: Antitumor activity of liposomal encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 1990;82:1706-1710.